Home › Funds › Nicholas Investment Partners, LP › DNTH
Nicholas Investment Partners, LP position in DNTH
DIANTHUS THERAPEUTICS INC · Health Care
Nicholas Investment Partners, LP reported holding 165,074 shares of DNTH (DIANTHUS THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$14.5M, representing 1.09% of its reported portfolio and ranking #28 among its reported holdings. Nicholas Investment Partners, LP has disclosed DNTH holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Nicholas Investment Partners, LP's DNTH position evolved
Nicholas Investment Partners, LP first disclosed a stake in DNTH in Q1 2026 at 51,250 shares (US$4.3M). The position peaked in Q2 2026 at 186,769 shares, worth US$18.2M. Across 3 filings, Nicholas Investment Partners, LP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 165,074 shares valued at US$14.5M — a reduction of -21,695 shares quarter over quarter.. Notable position changes include a 264% increase in Q2 2026 (shares fell 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 51.25K | $4.30M | New |
| Q2 2026 | 186.77K | $18.21M | Add |
| Q3 2026 | 165.07K | $14.53M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DNTH and 13F data
DNTH (DIANTHUS THERAPEUTICS INC) is a Health Care company. 54 other funds we track also report a position in DNTH — the largest reported positions include Fairmount Funds Management LLC (US$247.3M), Avidity Partners Management LP (US$205.1M), Octagon Capital Advisors LP (US$179.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DNTH
- Fairmount Funds Management LLC 2.54M sh · $247.33M · Q2 2026
- Avidity Partners Management LP 2.10M sh · $205.12M · Q2 2026
- Octagon Capital Advisors LP 1.84M sh · $179.53M · Q2 2026
- TCG Crossover Management, LLC 1.68M sh · $147.63M · Q3 2026
- FRED ALGER MANAGEMENT, LLC 1.30M sh · $126.97M · Q2 2026
- Venrock Adviser, LLC 1.18M sh · $115.03M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.13M sh · $109.70M · Q2 2026
- BAKER BROS. ADVISORS LP 852.16K sh · $83.07M · Q2 2026
- Cormorant Asset Management, LP 750.00K sh · $73.11M · Q2 2026
- BRAIDWELL LP 594.56K sh · $57.96M · Q2 2026
- Logos Global Management LP 500.00K sh · $44.02M · Q3 2026
- MPM BioImpact LLC 420.00K sh · $40.94M · Q2 2026
More on Nicholas Investment Partners, LP
FAQ
How long has Nicholas Investment Partners, LP held DNTH?
Nicholas Investment Partners, LP has disclosed DNTH holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Nicholas Investment Partners, LP's current position in DNTH?
As of Q3 2026, Nicholas Investment Partners, LP holds 165.07K shares of DNTH (DIANTHUS THERAPEUTICS INC), valued at $14.53M, representing 1.09% of its reported portfolio and ranking #28.
Has Nicholas Investment Partners, LP been buying or selling DNTH?
In the latest 13F filing (Q3 2026), Nicholas Investment Partners, LP reduced its position in DNTH. The position peaked in Q2 2026 at 186.77K shares.
Which other funds hold DNTH?
Other major institutional holders of DNTH include Fairmount Funds Management LLC, Avidity Partners Management LP, Octagon Capital Advisors LP, among 54 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.